glp 1 development history What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care Timeline for the evolution of

doi: 10.1530/acta.0.1240233 11 AversaSPellegrinoSBarberiIReiterRJGittoE

One expert noted that TB-500 was found to accelerate tumor growth in animal experiments, that other growth-related peptides might carry the same risk, and that other peptides could cause hormonal imbalances

Data extraction Two designated authors (AM and SS) meticulously extracted pertinent data from the included studies, including authorship details, publication timeline, samples of the study, mean demographic parameters (e.g., age, sex, baseline weight, and baseline BMI), type of bariatric surgery, prevalent background diseases, type of the GLP-1RAs therapy, the time of the initiation of the medical treatment, laboratory indices, amount of weight-change, and a comprehensive array of outcome measures, such as nausea, vomiting, diarrhea, and serious adverse events

Linkova, N.S., Drobintseva, A.O., Orlova, O.A